323 related articles for article (PubMed ID: 19139102)
21. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.
Gordon GM; Lambert QT; Daniel KG; Reuther GW
Biochem J; 2010 Dec; 432(2):255-65. PubMed ID: 20868368
[TBL] [Abstract][Full Text] [Related]
22. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
[TBL] [Abstract][Full Text] [Related]
23. Cell type-specific roles of Jak3 in IL-2-induced proliferative signal transduction.
Fujii H
Biochem Biophys Res Commun; 2007 Mar; 354(3):825-9. PubMed ID: 17266928
[TBL] [Abstract][Full Text] [Related]
24. Association of SRC-related kinase Lyn with the interleukin-2 receptor and its role in maintaining constitutive phosphorylation of JAK/STAT in human T-cell leukemia virus type 1-transformed T cells.
Shuh M; Morse BA; Heidecker G; Derse D
J Virol; 2011 May; 85(9):4623-7. PubMed ID: 21345943
[TBL] [Abstract][Full Text] [Related]
25. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.
Li Q; Li B; Hu L; Ning H; Jiang M; Wang D; Liu T; Zhang B; Chen H
Oncotarget; 2017 May; 8(21):34687-34697. PubMed ID: 28410228
[TBL] [Abstract][Full Text] [Related]
27. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors.
Murata T; Taguchi J; Puri RK
Blood; 1998 May; 91(10):3884-91. PubMed ID: 9573026
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
30. Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation.
Nelson BH; McIntosh BC; Rosencrans LL; Greenberg PD
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1878-83. PubMed ID: 9050873
[TBL] [Abstract][Full Text] [Related]
31. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
32. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
33. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
34. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.
Ruiz-Medina BE; Ross JA; Kirken RA
J Biol Chem; 2015 Aug; 290(34):20972-20983. PubMed ID: 26152718
[TBL] [Abstract][Full Text] [Related]
36. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3' kinase.
Sharfe N; Dadi HK; Roifman CM
Blood; 1995 Sep; 86(6):2077-85. PubMed ID: 7662955
[TBL] [Abstract][Full Text] [Related]
37. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
38. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
39. IL-2 induces conformational changes in its preassembled receptor core, which then migrates in lipid raft and binds to the cytoskeleton meshwork.
Pillet AH; Lavergne V; Pasquier V; Gesbert F; Thèze J; Rose T
J Mol Biol; 2010 Nov; 403(5):671-92. PubMed ID: 20816854
[TBL] [Abstract][Full Text] [Related]
40. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9.
Demoulin JB; Uyttenhove C; Van Roost E; DeLestré B; Donckers D; Van Snick J; Renauld JC
Mol Cell Biol; 1996 Sep; 16(9):4710-6. PubMed ID: 8756628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
